Do peptides help with fatty liver disease (MASLD and MASH)?
4 peptides are graded for fatty liver disease (MASLD and MASH) on this page. The strongest grade is human RCT evidence, for semaglutide, tirzepatide, survodutide, and tesamorelin. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for fatty liver disease (MASLD and MASH)?
Weight loss of 7 to 10% through diet and exercise, limiting alcohol, and treating diabetes, lipids, and blood pressure; fibrosis risk staging with FIB-4 and elastography; resmetirom or semaglutide for noncirrhotic MASH with moderate to advanced fibrosis; hepatology referral for advanced fibrosis or cirrhosis.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for fatty liver disease (MASLD and MASH)?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Semaglutide | Evidence: Human RCT evidence | ESSENCE phase 3: fibrosis improved without worsening steatohepatitis in 36.8% versus 22.4% on placebo; FDA approved as Wegovy for noncirrhotic MASH with F2 to F3 fibrosis. [6] |
| Tirzepatide | Evidence: Human RCT evidence | SYNERGY-NASH phase 2 (n = 190): MASH resolution without worsening fibrosis in 44% to 62% versus 10% on placebo; not approved for MASH. [7] |
| Survodutide | Evidence: Human RCT evidence | Phase 2 (n = 293): MASH improvement without worsening fibrosis in 43% to 62% versus 14% on placebo; phase 3 ongoing; not approved. [4] |
| Tesamorelin | Evidence: Human RCT evidence | In 61 adults with HIV and fatty liver, liver fat fell by a relative 37% versus placebo and 35% versus 4% reached normal liver fat; not approved for fatty liver. [5] [8] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for fatty liver disease (MASLD and MASH)?
Semaglutide, tirzepatide, survodutide, and tesamorelin have the strongest evidence among the peptides graded here, at human RCT evidence. Semaglutide: ESSENCE phase 3: fibrosis improved without worsening steatohepatitis in 36.8% versus 22.4% on placebo; FDA approved as Wegovy for noncirrhotic MASH with F2 to F3 fibrosis. Tirzepatide: SYNERGY-NASH phase 2 (n = 190): MASH resolution without worsening fibrosis in 44% to 62% versus 10% on placebo; not approved for MASH. Survodutide: Phase 2 (n = 293): MASH improvement without worsening fibrosis in 43% to 62% versus 14% on placebo; phase 3 ongoing; not approved. Tesamorelin: In 61 adults with HIV and fatty liver, liver fat fell by a relative 37% versus placebo and 35% versus 4% reached normal liver fat; not approved for fatty liver. [4] [6] [7] [8]
Is any peptide FDA approved for fatty liver disease (MASLD and MASH)?
Semaglutide, tirzepatide, and tesamorelin are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to fatty liver disease (MASLD and MASH). The other peptides graded here are not FDA approved. [5] [6] [7] [8] [9]
Has any peptide been tested in a randomized trial for fatty liver disease (MASLD and MASH)?
Yes, for semaglutide, tirzepatide, survodutide, and tesamorelin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [4] [6] [7] [8]
From the blog
- Tesamorelin vs HGH: how they differ and which is approved
Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions.
- Retatrutide benefits beyond weight loss: liver fat, blood sugar, and blood pressure
What retatrutide trials measured besides weight: liver fat, HbA1c, blood pressure, lipids, fat mass, and knee pain. What is proven, what is post hoc, and what is still unknown.
- Tesamorelin before and after: what the trials measured
Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.
Sources
- [1]Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025 (ESSENCE)PubMed 40305708, 2025
- [2]A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021PubMed 33185364, 2021
- [3]Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024 (SYNERGY-NASH)PubMed 38856224, 2024
- [4]A phase 2 randomized trial of survodutide in MASH and fibrosisPubMed 38847460, 2024
- [5]Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialPubMed 31611038, 2019
- [6]FDA prescribing information for Wegovy (semaglutide) injection, via DailyMedFDA, 2025
- [7]FDA prescribing information for Zepbound (tirzepatide) injection, via DailyMedFDA, 2025
- [8]FDA prescribing information for Egrifta SV (tesamorelin for injection), via DailyMedFDA, 2025
- [9]Drugs@FDA: FDA-approved drugs databaseFDA